To: Thomas Insel MD; Tommy Thompson Re: Published NIMH Prozac Trial Report Concealed Suicide Attempts by Teens ALLIANCE FOR HUMAN RESEARCH PROTECTION (AHRP) Tel. 212-595-8974 Fax: 212-595-9086 142 West End Ave. Suite 28P New York, NY 10023 Related Link: NIMH Response to AHRP Letter Board of Directors: Vera Hassner Sharav,…
Recent revelations indicate that pharmaceutical companies have selectively reported partial (favorable) clinical trial results from pediatric antidepressant trials and concealed evidence of harm from physicians, other health care professionals, and the public. It is universally agreed in the literature that failure to disclose all trial results compromises physicians’ ability to provide professional care – thereby increasing the likelihood of causing preventable harm. More generally, failure to disclose trial results in scientific publications taints the scientific literature (by rendering it not credible) and, as New York State Attorney General Elliot Spitzer charged recently, constitutes plain and simple fraud.
Family Wonders if Prozac Prompted School Shootings Sat, 26 Mar 2005 The New York Times reports that family members of Jeffe Weise, the Mennesota student who went on a shooting rampage, believe that Prozac "could have been the final straw" that triggered Weise to kill. “They kept upping the dose…
Pfizer issues prosecutors a manual to defend drug – Star Ledger Thu, 5 Aug 2004 In the May 14, 2004, settlement of a lawsuit initiated by a whistleblower, Pfizer pleaded guilty to criminal fraud in the promotion of Neurontin, and agreed to pay $430 million. https://ahrp.org/infomail/04/05/16.php A report in The…
Associated Press: More Details about FDA Warning Strattera Associated with Suicide Thu, 29 Sep 2005 On April 26, 2004, we wrote: “The Alliance for Human Research Protection is concerned that children who are prescribed the failed antidepressant, Strattera, may be exposed to undisclosed serious risks of harm. FDA’s-approved label states:…
Unlawful drug marketing: GlaxoSmithKline & 4,000 doctors Face Criminal Charges in Italy Mon, 7 Jun 2004 On March 25, 2004, the US Attorney in Pennsylvania commenced an investigation of Eli Lilly’s marketing promotion of Zyprexa (olanzapine), Prozac (fluoxetine) and Evista (raloxifene). On April 19, a class action lawsuit was filed…
TeenScreen – Angel of Mercy or Pill-Pusher for Drug Industry Thu, 14 Apr 2005 An investigative reporter has dug up the facts behind TeenScreen, the aggressive marketing scheme that targets America’s school children who are being “screened” for undetected mental problems – even though no accurate diagnostic screening tool for…
20% volunteers drop out after suicide in Eli Lilly’s duloxetine trial Thu, 12 Feb 2004 The Associated Press reports that nearly a fifth of the volunteers testing Eli Lilly’s antidepressant drug, duloxetine, dropped out after Traci Johnson, a 19-year old student committed suicide at a company laboratory. “Three participants in…
Healthy 19 year old volunteer suicides at Eli Lilly laboratory Tue, 10 Feb 2004 The Indianapolis Star reports (below) that Traci Johnson, a 19 year old healthy volunteer, one of 25 local paid volunteers committed suicide by hanging while testing Lilly’s drug, Duloxetine, at Lilly’s Laboratory for Clinical Research. Duloxetine…
AHRP Press Briefing Scientists Will Analyze SSRI Data – Families Will Tell Their Tragedies THE ALLIANCE FOR HUMAN RESEARCH PROTECTION (AHRP) 142 West End Ave. Suite 28P New York, NY 10023 January 27, 2004 Contact: Vera Hassner Sharav President, AHRP Tel. No: 212-595-8974 E-mail: Contact: Lisa Van Syckel Family Liaison…
Excerpt: The British drug authority has banned the use of most SSRI antidepressant drugs for the treatment of depression in children under 18, citing a two-to-threefold increased risk of suicidal behavior and lack of evidence of a benefit for depressed children. Two SSRIs – Paxil and Effexor – are no longer recommended by their manufacturer for use in children. Prozac is no longer recommended by Eli Lilly for children in the U.K.
In contrast to the British medicines authority review of the evidence, the FDA has refused to allow independent scientists to present documented evidence related to these drugs’ hazards and their failure to demonstrate a benefit for depressed children.
NAMI & Eli Lilly partners in bankrupting state Medicaid budgets – NYT Sat, 20 Dec 2003 The New York Times reports that Medicaid expenditure for prescription drugs has escalated to $27.5 billion. These costs are up 19% from last year. Antipsychotic drugs, such as Eli Lilly’s Zyprexa, eat up more…
